Skip to main content

Table 3 Univariable and multivariable analyses of OS

From: Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

  Univariable analysis Multivariable analysis
Variable   N HR (95% CI) p value HR (95% CI) p value
Age, years < 65 125 1 0.734
≥65 26 1.09 (0.67–1.77)  
Sex Male 137 1 0.678
Female 14 0.86 (0.42–1.77)  
ECOG PS 0 52 1 0.326
1–2 99 1.23 (0.82–1.84)  
Etiology HBV 134 1 0.784
Non-HBV 17 1.09 (0.60–1.98)  
Child-Pugh class A 140 1 0.118
B 11 1.73 (0.87–3.43)  
BCLC stage B 5 1 0.383
C 146 1.67 (0.53–5.26)  
MVI No 88 1 < 0.0001 1 0.125
Yes 63 2.17 (1.48–3.18)   1.37 (0.92–2.06)  
EHS No 15 1 0.775
Yes 136 1.10 (0.57–2.11)  
AFP (ng/mL) < 200 73 1 < 0.0001 1 0.005
≥200 77 2.27 (1.53–3.37)   1.80 (1.19–2.73)  
cfDNA (ng/μL) ≤0.71a) 76 1 < 0.0001 1 < 0.0001
> 0.71a) 75 3.50 (2.36–5.20)   2.51 (1.62–3.89)  
I-score ≤1637a) 76 1 < 0.0001 1 0.010
>1637a) 75 3.35 (2.24–5.01)   1.85 (1.16–2.96)  
  1. HR hazard ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, HBV hepatitis B virus, BCLC Barcelona Clinic Liver Cancer, MVI macroscopic vascular invasion, EHS extrahepatic spread, AFP alpha fetoprotein, cfDNA cell-free DNA
  2. a)Median value